Abstract
Pathological hypersexuality developed in 13 patients with PD and two patients ultimately diagnosed clinically with MSA. Hypersexuality began within 8 months after starting dopamine agonist therapy in 14 of 15 cases, including four on agonist monotherapy. It resolved in the four cases where the agonist was stopped, despite continued levodopa therapy. This was not an isolated behavioral problem in most, with additional compulsive or addictive behaviors coinciding in nine patients (60%). A systematic literature review of pathological hypersexuality in PD revealed similar medication histories; combining these cases with our series, 26 of 29 patients (90%) were on adjuvant dopamine agonists.
MeSH terms
-
Adult
-
Aged
-
Antiparkinson Agents / adverse effects*
-
Antiparkinson Agents / therapeutic use
-
Benzothiazoles
-
Catechols / adverse effects
-
Catechols / therapeutic use
-
Databases, Factual
-
Dopamine Agonists / adverse effects*
-
Dopamine Agonists / therapeutic use
-
Humans
-
Indoles / adverse effects
-
Indoles / therapeutic use
-
Levodopa / adverse effects
-
Levodopa / therapeutic use
-
Male
-
Mental Disorders / chemically induced
-
Mental Disorders / psychology
-
Middle Aged
-
Multiple System Atrophy / complications*
-
Multiple System Atrophy / drug therapy
-
Nitriles
-
Parkinson Disease / complications*
-
Parkinson Disease / drug therapy
-
Pramipexole
-
Sexual Dysfunctions, Psychological / chemically induced*
-
Thiazoles / adverse effects
-
Thiazoles / therapeutic use
Substances
-
Antiparkinson Agents
-
Benzothiazoles
-
Catechols
-
Dopamine Agonists
-
Indoles
-
Nitriles
-
Thiazoles
-
ropinirole
-
Levodopa
-
entacapone
-
Pramipexole